Leqembi: US OKs monthly maintenance dosing for Alzheimer’s drug
- 30-Jan-2025
The US Food and Drug Administration has approved monthly maintenance dosing for Japan’s Eisai and partner Biogen’s Alzheimer’s drug Leqembi, the companies said on Monday. The drug received standard U.S. approval in 2023 after showing it slowed cognitive decline in patients with the brain-wasting disease but growth has been slow, in part because its administration […]
Leqembi: Alzheimer’s drug from Eisai and Biogen faces setback
- 26-Jul-2024
The European Union’s drugs regulator has rejected Eisai and Biogen’s Leqembi treatment for early Alzheimer’s disease, saying the risk of serious brain swelling did not outweigh its small impact on slowing cognitive decline. The decision, released on Friday, is a blow to the companies as the drug faces slow take-up in the United States. Biogen’s […]
Leqembi: Alzheimer’s drug launched in China
- 28-Jun-2024
Eisai and Biogen have launched their Alzheimer’s treatment Leqembi in China, the third country after the United States and Japan, the companies said on Friday. Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer’s treatment proven to alter the course of the fatal, brain-wasting disease. The […]
3-part blood test for Alzheimer’s
- 11-Oct-2023
Labcorp on Wednesday began marketing to US physicians the first test for a trio of blood biomarkers it says can detect the hallmarks of Alzheimer’s, accelerating diagnosis of the brain-wasting disease and potentially helping patients access treatment. Labcorp’s Amyloid-Tau-Neurodegeneration (ATN) Profile is not precise enough to definitively diagnose Alzheimer’s, but offers a convenient way for […]
Intermittent fasting improves Alzheimer’s pathology
- 26-Aug-2023
One of the hallmarks of Alzheimer’s disease is disruption to the body’s circadian rhythm, the internal biological clock that regulates many of our physiological processes. Nearly 80 percent of people with Alzheimer’s experience these issues, including difficulty sleeping and worsening cognitive function at night. However, there are no existing treatments for Alzheimer’s that target this […]
LEQEMBI: Alzheimer’s drug gets US approval
- 07-Jul-2023
Eisai and Biogen’s Leqembi won a coveted standard approval nod from the U.S. Food and Drug Administration on Thursday, the first Alzheimer’s treatment to achieve that goal, clearing the way for wider insurance coverage of the drug. The FDA decision marks a new milestone for a fatal disease that has eluded drugmakers’ efforts for decades. […]
Drug slows Alzheimer’s progression by 35% in trial
- 03-May-2023
An experimental Alzheimer’s drug developed by Eli Lilly slowed cognitive decline by 35% in a closely watched late-stage trial, the company said on Wednesday, raising hopes for a second effective treatment for the brain-wasting disease. Eli Lilly’s shares opened at a record high of $415 on Wednesday, and were up 4.2% at $421.01 in early […]
Govt taking steps for treatment of those with Alzheimer’s and dementia: Yasmeen
- 21-Sep-2019
Punjab Minister for Health Dr. Yasmeen Rashid says all-out facilities will be provided to the patients of Alzheimer's and dementia in the province.
Experts call for diagnosing Alzheimer’s by brain changes, not symptoms
- 10-Apr-2018
TAMPA, US: In an effort to speed research toward a cure for the most common form of dementia, experts urged a new framework Tuesday to diagnose Alzheimer’s disease using biological clues, rather than symptoms of memory loss. Alzheimer’s affects some 44 million people around the world, but remains poorly understood, with no effective treatments despite […]
Aerobic exercise slows cognitive decline in Alzheimer’s disease
- 05-Mar-2018
WASHINGTON: Cardiovascular exercise training may help slow the decline in brain function seen in Alzheimer’s patients, a new review of past research suggests. Researchers assessed data from 19 studies conducted between 2002 and 2015 that examined the effects of exercise on cognitive ability in 1,145 people at risk of or diagnosed with Alzheimer’s disease. Nearly […]